mdaOpinion

Statement from the Muscular Dystrophy Association on Court Decision Affecting Medicaid Community Engagement Requirements

The Muscular Dystrophy Association (MDA) recognizes today’s decision by the U.S. District Court for the District of ...
mda

ACT for ALS Reauthorization Advances to the President After Today’s Senate Action

Washington, D.C., Monday, September 28, 2026 – The Muscular Dystrophy Association applauds the United States Senate for passing the House’s version of the ACT for ALS (Accelerating Access to Critical ...
mda

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment

New York, Friday, September 11, 2026 – The Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of ...
mda

MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities

Free, in-person events unite families, clinicians, researchers, and advocates to accelerate progress, advance care, and strengthen connection across the neuromuscular community. New York, Monday, June ...
mda

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

New York, Friday, May 8, 2026 – The Muscular Dystrophy Association (MDA) today welcomed the U.S. Food and Drug Administration’s (FDA) approval for label expansion of VYVGART® (efgartigimod alfa-fcab) ...
mda

The 2026 MDA Clinical & Scientific Conference Highlights Breakthroughs in Neuromuscular Research, Innovative Therapies, and Patient Care

Orlando, FL, Thursday, March 12, 2026 – The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees from 40 countries to ...
mda

Muscular Dystrophy Association Supports National Launch of Champion Insights Study to Investigate ALS Risk in Fire Fighters and Other High-Performance Populations

NEW YORK, NY, Tuesday, February 4, 2026 – The Muscular Dystrophy Association (MDA) announced its support of the nationwide launch of Champion Insights, a new research initiative designed to understand ...
mda

MDA Announces 2026 National Ambassador Lily Sander Following Landmark Years of National Advocacy

Lily Sander will commence her second year as MDA National Ambassador by speaking at the largest global gathering of the neuromuscular community on March 9 at the 2026 MDA Clinical & Scientific ...
mda

Help Shape the Future of Neuromuscular Research

The Muscular Dystrophy Association (MDA) is launching the next phase of its national patient data platform — and you’re invited to be part of it. MOVR 2.0 is a new generation platform. It is a secure, ...
mda

U.S. Department of Health and Human Services Adds Duchenne to Recommended Uniform Screening Panel

WASHINGTON, DC — Tuesday, December 16, 2025 — Today, the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening ...
mda

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the ...

NEW YORK, Monday, December 8, 2025 – The Muscular Dystrophy Association (MDA) announced today that John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), will deliver ...